Clinical trial
A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
NCT02448420 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Palbociclib in Combination With Trastuzumab and Endocrine Therapy in Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer (PATRICIA II)
- Lead sponsor
- SOLTI Breast Cancer Research Group
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 31, 2015
- Completion date
- November 30, 2023
- Enrollment
- 73 (actual)
- Sites
- 35
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic breast cancer